Publication

Article

Supplements and Featured Publications

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Volume1
Issue 1

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

This publication includes a summary of data on recent therapeutic advances in treating metastatic HER2-positive breast cancer that was presented during a series of 4 live regional broadcasts across the United States (California, Illinois, Texas, and Washington). Medical oncologists specializing in the treatment of breast cancer across those regions provide key insights on factors that influence planning and treatment selection.

Download Issue PDF
Articles in this issue
breast cancer
Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Related Videos
Peter Forsyth, MD
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Thomas Westbrook, MD, assistant professor, Rush University Medical Center
Related Content
Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center
November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Breast Cancer
November 18th 2024

Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Breast Cancer
November 13th 2024

IBI354 Shows Efficacy and Safety in HER2+ and HER2-Low Advanced Breast Cancer

Kari Wisinski, MD, the Endowed Professor of Hematology and Oncology and chief of the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison
November 12th 2024

Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management